What is HC Wainwright's Forecast for ARWR FY2025 Earnings?

Key Points

• HC Wainwright has revised its FY2025 earnings estimate for Arrowhead Pharmaceuticals to $(0.23) per share, down from $(0.20), while maintaining a "Buy" rating and price target of $80.00.
• The current consensus estimate for Arrowhead Pharmaceuticals' full-year earnings stands at $(2.42) per share, indicating significant projected losses for the coming years.
• Insider James C. Hamilton sold 15,000 shares of ARWR at an average price of $30, reducing his stake in the company by 6.07%.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Analysts at HC Wainwright lowered their FY2025 earnings per share estimates for Arrowhead Pharmaceuticals in a research report issued to clients and investors on Monday, September 15th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will earn ($0.23) per share for the year, down from their prior estimate of ($0.20). HC Wainwright currently has a "Buy" rating and a $80.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' Q4 2025 earnings at ($0.38) EPS, Q1 2026 earnings at $1.83 EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.23) EPS, Q4 2026 earnings at ($1.23) EPS, FY2026 earnings at ($1.66) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($3.36) EPS and FY2029 earnings at ($1.61) EPS.

Several other equities research analysts have also recently weighed in on the stock. Royal Bank Of Canada lowered their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research report on Friday, August 8th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Finally, TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Trading Down 2.6%

ARWR stock traded down $0.82 during mid-day trading on Wednesday, reaching $30.69. The company had a trading volume of 4,937,943 shares, compared to its average volume of 2,067,065. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The company has a market capitalization of $4.24 billion, a PE ratio of -23.98 and a beta of 1.00. The firm has a 50 day moving average of $20.93 and a 200 day moving average of $16.86. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $31.67.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The business had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same quarter in the prior year, the company earned ($1.38) EPS.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the company's stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $30.00, for a total transaction of $450,000.00. Following the transaction, the insider owned 232,122 shares in the company, valued at approximately $6,963,660. This represents a 6.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 40,000 shares of company stock worth $1,025,000. Corporate insiders own 4.30% of the company's stock.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. Marshall Wace LLP grew its position in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock valued at $34,065,000 after buying an additional 2,096,238 shares during the period. Norges Bank acquired a new stake in Arrowhead Pharmaceuticals during the second quarter valued at $30,414,000. Vanguard Group Inc. grew its position in Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock valued at $168,201,000 after buying an additional 1,018,273 shares during the period. Finally, Aberdeen Group plc grew its position in Arrowhead Pharmaceuticals by 138.4% during the first quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company's stock valued at $13,668,000 after buying an additional 622,752 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.